JP Morgan Maintains Overweight on Travere Therapeutics, Raises Price Target to $23
Travere Therapeutics Analyst Ratings
J.P. Morgan Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $23
J.P. Morgan analyst Anupam Rama maintains $Travere Therapeutic(TVTX.US)$ with a buy rating, and adjusts the target price from $20 to $23.According to TipRanks data, the analyst has a success rate of 4
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference
Travere Therapeutics Is Maintained at Buy by Canaccord Genuity